PT - JOURNAL ARTICLE AU - Berzenji, Lawek AU - Michaux, Dario AU - Yogeswaran, Suresh Krishan AU - Van Breussegem, Annemie AU - Lauwers, Patrick AU - Raskin, Jo AU - Hendriks, Jeroen AU - Van Meerbeeck, Jan AU - Van Schil, Paul TI - Pleurectomy/decortication for malignant pleural mesothelioma: a single-centre experience AID - 10.1183/13993003.congress-2020.1718 DP - 2020 Sep 07 TA - European Respiratory Journal PG - 1718 VI - 56 IP - suppl 64 4099 - https://publications.ersnet.org//content/56/suppl_64/1718.short 4100 - https://publications.ersnet.org//content/56/suppl_64/1718.full SO - Eur Respir J2020 Sep 07; 56 AB - Objective: The role and timing of surgery for malignant pleural mesothelioma (MPM) in a multimodal setting remains a controversial topic. Earlier studies suggest that pleurectomy/decortication (P/D) achieves similar or better oncological results and overall survival rates compared to extrapleural pneumonectomy. The aim of this study is to investigate outcomes in patients undergoing P/D for MPM at a single centre.Methods: Clinical and pathological characteristics of MPM patients treated by P/D between January 2013 and January 2020 were reviewed. Overall 30- and 90-day mortality and 1- and 2-year survival rates were calculated. Univariate and regression analyses of factors related to long-term survival were performed. Kaplan-Meier curves and the long-rank test were used to analyse differences between induction and adjuvant chemotherapy.Results: A total of 41 patients (31 male and 9 female) with a mean age of 65±7.8 years underwent P/D for MPM. The 30- and 90-day mortality rates were 2.5% and 5.4%, respectively. Overall 1-, and 2-year survival (OS) rates were 67.6% and 41.4%, respectively. Progressive disease occurred in 63.2% of all patients. Multiple regression analysis revealed age>70 years, asbestos exposure, T-status, N-status, tumour pathology, (neo)adjuvant therapy, postoperative morbidity, and progressive disease as significant prognostic factors (p<0.05). Prognosis was significantly better in the induction chemotherapy group compared to the adjuvant chemotherapy group (p=0.03).Conclusion: Patients treated with P/D for MPM in a multimodal setting have acceptable overall survival rates. The findings suggest that induction chemotherapy results in better OS than adjuvant chemotherapy.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 1718.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).